Characterization of YM-58483/BTP2, a novel store-operated Ca2+ entry blocker, on T cell-mediated immune responses in vivo

International Immunopharmacology

Volumn 8, Issue 13-14, 2008, Pages 1787-1792

  Ohga, Keiko ^a   Takezawa, Ryuichi ^a   Arakida, Yasuhito ^a   Shimizu, Yasuaki ^a   Ishikawa, Jun ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

BTP2; Ca2+ release activated Ca2+ channel; Store operated Ca2+ entry; T cell; YM 58483

Indexed keywords

4 METHYL 4' [3,5 BIS(TRIFLUOROMETHYL) 1H PYRAZOL 1 YL] 1,2,3 THIADIAZOLE 5 CARBOXANILIDE; CALCIUM CHANNEL BLOCKING AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; UNCLASSIFIED DRUG; YM 58483;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG DOSE COMPARISON; FEMALE; GRAFT VERSUS HOST REACTION; IC 50; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SHEEP ERYTHROCYTE; SPLEEN;

ANILIDES; ANIMALS; B-LYMPHOCYTES; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; GRAFT VS HOST DISEASE; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; THIADIAZOLES;

EID: 55249104159     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.08.016     Document Type: Article

References (43)

1. Belkacemi L., Bedard I., Simoneau L., and Lafond J. Calcium channels, transporters and exchangers in placenta: a review. Cell Calcium 37 (2005) 1-8
2. Parekh A.B., and Putney Jr. J.W. Store-operated calcium channels. Physiol Rev 85 (2005) 757-810
3. Fasolato C., Hoth M., and Penner R. A GTP-dependent step in the activation mechanism of capacitative calcium influx. J Biol Chem 268 (1993) 20737-20740
4. Parekh A.B., and Penner R. Store depletion and calcium influx. Physiol Rev 77 (1997) 901-930
5. Ishikawa J., Ohga K., Yoshino T., Takezawa R., Ichikawa A., Kubota H., et al. A pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ influx and IL-2 production in T lymphocytes. J Immunol 170 (2003) 4441-4449
6. Ma H.T., Venkatachalam K., Parys J.B., and Gill D.L. Modification of store-operated channel coupling and inositol trisphosphate receptor function by 2-aminoethoxydiphenyl borate in DT40 lymphocytes. J Biol Chem 277 (2002) 6915-6922
7. Mason M.J., Mayer B., and Hymel L.J. Inhibition of Ca2+ transport pathways in thymic lymphocytes by econazole, miconazole, and SKF 96365. Am J Physiol 264 (1993) C654-662
8. Lewis R.S. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 19 (2001) 497-521
9. Peinelt C., Vig M., Koomoa D.L., Beck A., Nadler M.J., Koblan-Huberson M., et al. Amplification of CRAC current by STIM1 and CRACM1 (Orai1).[see comment]. Nat Cell Biol 8 (2006) 771-773
10. Soboloff J., Spassova M.A., Tang X.D., Hewavitharana T., Xu W., and Gill D.L. Orai1 and STIM reconstitute store-operated calcium channel function. J Biol Chem 281 (2006) 20661-20665
11. Vig M., Peinelt C., Beck A., Koomoa D.L., Rabah D., Koblan-Huberson M., et al. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 312 (2006) 1220-1223
12. Prakriya M., Feske S., Gwack Y., Srikanth S., Rao A., and Hogan P.G. Orai1 is an essential pore subunit of the CRAC channel. Nature 443 (2006) 230-233
13. Yeromin A.V., Zhang S.L., Jiang W., Yu Y., Safrina O., and Cahalan M.D. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature 443 (2006) 226-229
14. Schlesier M., Niemeyer C., Duffner U., Henschen M., Tanzi-Fetta R., Wolff-Vorbeck G., et al. Primary severe immunodeficiency due to impaired signal transduction in T cells. Immunodeficiency 4 (1993) 133-136
15. Feske S., Gwack Y., Prakriya M., Srikanth S., Puppel S.H., Tanasa B., et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441 (2006) 179-185
16. Feske S., Prakriya M., Rao A., and Lewis R.S. A severe defect in CRAC Ca2+ channel activation and altered K+ channel gating in T cells from immunodeficient patients. J Exp Med 202 (2005) 651-662
17. Zitt C., Strauss B., Schwarz E.C., Spaeth N., Rast G., Hatzelmann A., et al. Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. J Biol Chem 279 (2004) 12427-12437
18. He L.P., Hewavitharana T., Soboloff J., Spassova M.A., and Gill D.L. A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. J Biol Chem 280 (2005) 10997-11006
19. Takezawa R., Cheng H., Beck A., Ishikawa J., Launay P., Kubota H., et al. A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 channel activity. Mol Pharmacol 69 (2006) 1413-1420
20. Chen Y., Smith M.L., Chiou G.X., Ballaron S., Sheets M.P., Gubbins E., et al. TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators. Cell Immunol 220 (2002) 134-142
21. Djuric S.W., BaMaung N.Y., Basha A., Liu H., Luly J.R., Madar D.J., et al. 3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator. J Med Chem 43 (2000) 2975-2981
22. Trevillyan J.M., Chiou X.G., Chen Y.W., Ballaron S.J., Sheets M.P., Smith M.L., et al. Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. J Biol Chem 276 (2001) 48118-48126
23. Ohga K., Takezawa R., Yoshino T., Yamada T., Shimizu Y., and Ishikawa J. The suppressive effects of YM-58483/BTP-2, a store-operated Ca(2+) entry blocker, on inflammatory mediator release in vitro and airway responses in vivo. Pulm Pharmacol Ther 21 (2008) 360-369
24. Yoshino T., Ishikawa J., Ohga K., Morokata T., Takezawa R., Morio H., et al. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models. Eur J Pharmacol 560 (2007) 225-233
25. Yonetoku Y., Kubota H., Okamoto Y., Toyoshima A., Funatsu M., Ishikawa J., et al. Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 1: synthesis and inhibitory activity of 5-(1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamides. Bioorg Med Chem 14 (2006) 4750-4760
26. Furukawa Y., Matsumori A., Hirozane T., Matsui S., Sato Y., Ono K., et al. Immunomodulation by an adenylate cyclase activator, NKH477, in vivo and vitro. Clin Immunol Immunopathol 79 (1996) 25-35
27. Rus V., Svetic A., Nguyen P., Gause W.C., and Via C.S. Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. Regulatory role of donor CD8+ T cells. J Immunol 155 (1995) 2396-2406
28. Williamson E., Garside P., Bradley J.A., and Mowat A.M. IL-12 is a central mediator of acute graft-versus-host disease in mice. J Immunol 157 (1996) 689-699
29. Jaksch M., and Mattsson J. The pathophysiology of acute graft-versus-host disease. Scand J Immunol 61 (2005) 398-409
30. Kudlacz E., Perry B., Sawyer P., Conklyn M., McCurdy S., Brissette W., et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 4 (2004) 51-57
31. Jordan W.J., and Ritter M.A. Optimal analysis of composite cytokine responses during alloreactivity. J Immunol Methods 260 (2002) 1-14
32. Shustov A., Nguyen P., Finkelman F., Elkon K.B., and Via C.S. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. J Immunol 161 (1998) 2848-2855
33. Buhlmann J.E., Gonzalez M., Ginther B., Panoskaltsis-Mortari A., Blazar B.R., Greiner D.L., et al. Sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 162 (1999) 4373-4376
34. Ogawa S., Nagamatsu G., Watanabe M., Watanabe S., Hayashi T., Horita S., et al. Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease. J Immunol 167 (2001) 5741-5748
35. Grabbe S., and Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 19 (1998) 37-44
36. Kamada H., Inoue N., Takaoka Y., Nakagami K., Mori H., and Nagai H. Effect of mizoribine on effector T cell-mediated immune responses in mice. Biol Pharm Bull 19 (1996) 1136-1140
37. Reddy M.P., Webb E.F., Cassatt D., Maley D., Lee J.C., Griswold D.E., et al. Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses. Int J Immunopharmacol 16 (1994) 795-804
38. Wang B., Fujisawa H., Zhuang L., Freed I., Howell B.G., Shahid S., et al. CD4+ Th1 and CD8+ type 1 cytotoxic T cells both play a crucial role in the full development of contact hypersensitivity. J Immunol 165 (2000) 6783-6790
39. Cohen D.J., Loertscher R., Rubin M.F., Tilney N.L., Carpenter C.B., and Strom T.B. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 101 (1984) 667-682
40. Karanikolas G., Charalambopoulos D., Andrianakos A., Antoniades C., and Katsilambros N. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J Rheumatol 33 (2006) 486-489
41. Lock S.H., Kay A.B., and Barnes N.C. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 153 (1996) 509-514
42. Malekzadeh R., Nasseri-Moghaddam S., Kaviani M.J., Taheri H., Kamalian N., and Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 46 (2001) 1321-1327
43. Ryeom S., Greenwald R.J., Sharpe A.H., and McKeon F. The threshold pattern of calcineurin-dependent gene expression is altered by loss of the endogenous inhibitor calcipressin. Nat Immunol 4 (2003) 874-881